It's just not possible that this many images all have the same background.
In the quiet infrastructure of modern biology, where Y-shaped molecules serve as the essential keys to unlocking protein identity, a pair of integrity researchers have surfaced evidence that more than a hundred images in Thermo Fisher Scientific's antibody catalogue bear signs of manipulation — duplicated bands, painted backgrounds, and statistically impossible shared imagery across separate experiments. The discovery does not arrive in isolation but lands atop a long-simmering crisis of trust in commercial research tools, where a majority of antibodies have already been found to underperform their promises. It raises, once again, the oldest question in science: how much can a researcher trust what they did not themselves verify?
- Two integrity researchers stumbled upon a pattern no legitimate experiment could produce — protein bands with identical squiggly shapes appearing flipped and rotated across supposedly independent test images.
- What began as one researcher's casual catalogue browse cascaded into a crowdsourced audit, ultimately surfacing 127 problematic images tied to one of the world's largest scientific suppliers.
- The findings land on already fractured ground: a 2023 survey showed more than half of commercial antibodies fail to perform as advertised, in a market valued at over $250 billion annually.
- Thermo Fisher has pledged an internal review and future transparency around 'optimized' images, but has stopped short of admitting wrongdoing or connecting the alterations to product quality.
- Scientists remain divided — some argue manipulated catalogue images and defective antibodies are separate problems, while others suspect the alterations reveal something darker about how products are validated before sale.
In late May, two researchers who track problems in scientific data documented something striking: more than a hundred images in Thermo Fisher Scientific's product catalogue appear to have been altered. Their database, published on May 28, catalogues 127 problematic images — some involving minor visual tweaks, others far more serious, including duplicated protein bands, manually painted backgrounds, and fifty test results sharing identical backgrounds, a statistical impossibility pointing to wholesale image copying.
The investigation began almost by accident. Sholto David, a molecular biologist in Oxford, was browsing the catalogue for western blot images when he noticed protein bands with a distinctive squiggly shape appearing multiple times, sometimes flipped or rotated — something that should never occur in legitimate data. He posted the observation online, and within days Reese Richardson, a metascientist at Northwestern University, had joined the effort and found 105 additional problematic images.
The discovery arrives amid a well-documented reliability crisis in the antibody industry. Antibodies are indispensable research tools, yet a 2023 survey found more than half of commercial antibodies fail to work as specified — a persistent problem across a market worth over $250 billion annually. Thermo Fisher alone stocks more than 250,000 primary antibodies. Catalogue images are meant to demonstrate that products work cleanly; manipulated images make the obvious question unavoidable.
Thermo Fisher responded swiftly, pledging a comprehensive internal review and promising to flag images that have been optimized for presentation. The statement stopped short of acknowledging wrongdoing or linking the alterations to product quality. Some researchers, including the lead scientist of an independent antibody-testing programme, argue the two issues are likely unrelated. Others, like cancer researcher Jennifer Byrne, suggest the manipulations may point to deeper problems in how the company validates its products. For now, scientists are left where they have long stood — needing to independently verify that what they purchase actually works.
In late May, two researchers who track problems in scientific data made a discovery that has unsettled the world of commercial antibody suppliers: more than a hundred images in Thermo Fisher Scientific's product catalogue appear to have been altered. The finding, documented in an online database on May 28, catalogues 127 problematic images tied to antibodies the company sells to laboratories worldwide. Some alterations are subtle—minor tweaks to make images clearer or more visually appealing. Others are far more troubling: duplicated protein bands, manually painted-over backgrounds to hide flaws, and most strikingly, fifty separate test results that share identical backgrounds, a statistical impossibility that suggests wholesale copying and pasting.
The investigation began almost by accident. Sholto David, a molecular biologist in Oxford who studies research integrity, was browsing Thermo Fisher's catalogue looking for specific western blot images when he noticed something odd. Several protein bands in one image had a distinctive squiggly shape that appeared multiple times, sometimes flipped or rotated. In a legitimate western blot—the standard technique used to detect and identify proteins—such repetition should never occur naturally. David posted his observation on social media, expecting little response. Instead, other researchers piled on, frustrated and alarmed. Within days, Reese Richardson, a metascientist at Northwestern University, joined the effort and found 105 additional problematic images. The scope of the problem became impossible to ignore.
This discovery arrives at a moment when the antibody industry is already under scrutiny. Antibodies are Y-shaped molecules that bind to specific proteins, making them indispensable tools for biological research. Yet for years, scientists have complained that commercial antibodies often fail to perform as advertised—a problem so widespread it has been called a reliability crisis. A 2023 survey of 614 commercial antibodies found that more than half did not work as specified. The global antibody market is worth more than $250 billion annually, with hundreds of companies collectively selling over seven million antibodies. Thermo Fisher alone stocks more than 250,000 primary antibodies in its catalogue.
When companies advertise their antibodies, they include supporting data meant to prove the products work. These data typically include western blots showing clean, distinct protein bands—evidence that the antibody binds selectively to its target. Fuzzy results or multiple bands suggest the antibody is binding to unintended proteins, a sign of poor quality. The images in Thermo Fisher's catalogue are meant to demonstrate that the company's antibodies produce clean, reliable results. If those images have been manipulated, the question becomes unavoidable: what does that say about the products themselves?
Thermo Fisher's response was swift. Sandy Pound, the company's chief communications officer, issued a statement saying the company takes the matter seriously and has begun a comprehensive internal review. Going forward, the company said, it will inform users when images have been optimized for presentation and clarity. The statement stopped short of acknowledging that the alterations were inappropriate or that they might reflect problems with the underlying products. This distinction matters. Image manipulation does not necessarily mean the antibodies themselves are defective—a point some researchers have emphasized. Carl Laflamme, lead scientist for a programme that independently tests commercial antibodies, argues there is probably no connection between altered catalogue images and the broader antibody reliability crisis, which has persisted for years regardless of how companies present their data online.
Yet others are less certain. Jennifer Byrne, a cancer researcher at the University of Sydney, suggested that the manipulations might indicate deeper problems with how the company validates its products. The discovery has reignited a familiar tension in research: how much can scientists trust the tools they buy from commercial suppliers? And if a company is willing to alter images in its own catalogue, what does that suggest about its quality control? The debate is unlikely to be resolved quickly. For now, researchers are left with the same problem they have faced for years—the need to independently verify that the antibodies they purchase actually work as promised.
Citações Notáveis
It's just not possible that this many images all have the same background.— Reese Richardson, metascientist at Northwestern University
We take this matter seriously and have initiated a comprehensive internal review. Moving forward, we will ensure that website users are informed that antibody images may have been optimized for presentation and clarity.— Sandy Pound, chief communications officer for Thermo Fisher Scientific
A Conversa do Hearth Outra perspectiva sobre a história
Why would a company alter images in a product catalogue? What's the incentive?
The alterations range from minor—smoothing out a background to make the image clearer—to major, like copying and pasting protein bands. The minor ones might be done by someone thinking they're just making the image look nicer for presentation. The major ones suggest either carelessness or an attempt to hide poor results.
But does a manipulated image necessarily mean the antibody is bad?
That's the central question right now. The image is meant to prove the antibody works. If the image is fake, it proves nothing. But some researchers argue the antibody itself could still be fine—the image manipulation might be a separate problem, a failure of presentation rather than product quality.
How many antibodies are we talking about here?
Thermo Fisher has over 250,000 primary antibodies in its catalogue. The researchers found 127 problematic images. So it's a small fraction of the total inventory, but it's enough to raise serious questions about how the company validates and presents its products.
What does a western blot actually show?
It's a test that detects specific proteins in a sample. If the antibody works correctly, you see a clean, distinct band. If it's binding to the wrong proteins too, you see multiple bands or fuzzy results. The images in the catalogue are supposed to show clean bands—proof the antibody is selective and reliable.
So if the bands are duplicated or copied, what does that tell you?
It tells you the image is fake. You can't have the exact same protein band appear multiple times in different samples, or have fifty different test results share identical backgrounds. That's not biology—that's image editing.
What happens now?
Thermo Fisher says it will be more transparent about which images have been optimized. But researchers are asking harder questions: if this happened in the catalogue, what about the actual products? And if the company wasn't careful about images, how careful were they about validation?